Prof. Seung-Yong Seong

Shaperon
South Korea

Abstract Title: Efficacy of GPCR19 Agonists HY209 and HY3 in Atopic Dermatitis: Translational Results from Murine and Canine Models

Biography:

Seung-Yong Seong is a professor at Seoul National University College of Medicine and Director of the Wide River Institute of Immunology. He is renowned for his pioneering research on the innate immune system, including the development of the DAMP model with Polly Matzinger, and for his studies on infectious diseases. Professor Seong has published widely in leading journals, is an active member of major microbiology and immunology societies, and has received numerous national and international awards for his significant scientific contributions.

Research Interest:

Atopic dermatitis (AD) remains a significant unmet medical need, and our studies demonstrate the efficacy of the GPCR19 agonist platform across species and administration routes. HY209, a GPCR19 agonist, has shown promising results in both murine and canine models. In murine models, topical application of HY209 significantly improved AD symptoms by inhibiting key inflammatory pathways. Translating these findings to a canine model, oral administration of HY209 (6 mg/kg) to six dogs with naturally occurring AD demonstrated substantial therapeutic benefit. The canine study results showed marked reductions in pruritus as measured by PVAS scores, with improvements observed from baseline through the 28-day treatment period. The CADESI-04 assessment also revealed significant decreases in lesion severity over the same timeframe. Treatment was administered twice daily (b.i.d.) for the first 14 days, followed by once daily (q.d.) dosing through day 28. Photographic documentation confirmed visible improvements in affected paw areas, with noticeable reduction in erythema and inflammation. HY3, another GPCR19 agonist compound, was evaluated through oral administration in DNCB-induced atopic mice. This second-generation compound showed marked clinical improvement as measured by EASI scores, with efficacy comparable to that achieved with the JAK inhibitor oclacitinib at the same dosage (10 mg/kg). Collectively, these results indicate that both HY209 and HY3 are promising therapeutic candidates for AD, offering efficacy through both topical and oral routes, and support further clinical development.